How a lobbying firm tied to Trump Jr helped Chinese pharma company beat US national security challenge

Weeks later, CFIUS dismissed FastWave's filing, citing material misstatements in the company's submissions rather than addressing national security concerns. The rejections effectively allowed the Chinese firm to retain its 40 per cent stake in the US startup.